Given that PIKfyve suppresses DC function, we reason that PIKfyve inhibitors may be selected to treat cancers with high PIKfyve expression in tumors and DCs, thereby effectively targeting both tumors and the immune system. This evidence concerns the gene PIKFYVE and cancer.